An Introduction to Dermatological Conditions
Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Dermatological Conditions Content
Christian Vestergaard, EADV 2021: Biologics for Paediatric Skin Diseases
It was a pleasure to meet Dr Christian Vestergaard (Aarhus University Hospital, Aarhus, Denmark) to discuss the use of biologics in the treatment of paediatric skin diseases. His presentation entitled ‘The use of biological drugs for skin diseases in children’ was presented at the EADV 30th Congress, 29 Sep – 2 Oct 2021. Questions What […]
Rosalie Luiten, EADV 2021: The Role of Resident Memory T-cells in Vitiligo and Tumour Immunity
touchIMMUNOLOGY were delighted to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the role of resident memory T cells in autoimmune vitiligo and tumour immunity, and how they could be used as a therapeutic target. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the […]
Rosalie Luiten, EADV 2021: The Link between Vitiligo and Melanoma
It was a pleasure to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the immunological link between vitiligo and melanoma. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Questions How are vitiligo and melanoma linked? […]
Brian Kim, EADV 2021: Advances in Therapeutics for Chronic Pruritus
In this interview, we talk with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) about the current unmet need in the treatment of pruritus and how the therapeutic landscape is changing. His presentation entitled ‘New frontiers in itch therapy‘ was given at the EADV 30th Congress, 29 Sep – 2 Oct […]
Sonja Ständer, EADV 2021: New Therapies for Chronic Pruritus and Prurigo
touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo. Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Disclosures: Prof. Sonja Ständer has acted as an investigator […]
Sonja Ständer, EADV 2021: Nemolizumab in the Treatment of Prurigo Nodularis
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab. Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep […]
Sorena Kiani, EAACI 2021: Berotralstat in the Treatment of Hereditary Angioedema
touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema. Questions 1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53) 2. What is berotralstat and what is the rationale for its use in HAE? (01:53-03:17) […]
Marcus Maurer, EAACI 2021: Avapritinib for Advanced Systemic Mastocytosis – The PATHFINDER Study
touchIMMUNOLOGY joins Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study. Questions Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26) […]
Marcus Maurer, EAACI 2021: CDX-0159 for the Treatment of Urticaria
touchIMMUNOLOGY were delighted to talk with Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the Phase 1a study of CDX-0159 in patients with chronic inducible urticaria. Questions What is CDX-0159 and what is the rationale for its use in patients with chronic inducible urticaria? (0:26) Could you tell us […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!